Ellis, Anne K. http://orcid.org/0000-0002-0725-2353
Foran, Vanessa
Kaplan, Alan
Mitchell, Patrick D.
Funding for this research was provided by:
AstraZeneca Canada
Article History
Received: 30 March 2022
Accepted: 27 May 2022
First Online: 11 June 2022
Declarations
:
: Not applicable.
: The individual who wrote the patient experience section provided written consent for publication of the excerpt.
: A.K. Ellis has participated in advisory boards for ALK-Abelló, AstraZeneca, Bausch Health, Circassia Ltd, GlaxoSmithKline, LEO Pharma, Johnson & Johnson, Merck, Mylan, Novartis, Pediapharm and Pfizer, has been a speaker for ALK, AstraZeneca, Bausch Health, Boehringer-Ingelheim, CACME, Meda, Medexus, Miravo, Mylan, Merck, Novartis, Pfizer, The ACADEMY, and Takeda. Her institution has received research grants from AstraZeneca, Bayer, LLC, Circassia Ltd, Green Cross Pharmaceuticals, GlaxoSmithKline, Sun Pharma, Merck, Novartis, Pfizer, Regeneron and Sanofi. She has also served as an independent consultant to Allergy Therapeutics, Bayer, LLC, Ora Inc., and Regeneron in the past. V. Foran participates on advisory boards for GlaxoSmithKline, AstraZeneca, Pfizer, and Asthma Canada, has received educational grants from GlaxoSmithKline, AstraZeneca, Pfizer, Sanofi Genzyme, Sanofi Pasteur, and Novartis. A. Kaplan has served on advisory Boards or Speakers Bureaus for AstraZeneca, Behring, Boehringer- Ingelheim, Cipla, Covis, GlaxoSmithKline, Merck, Novartis, Pfizer Sanofi, Teva, Trudel, and Valeo. P.D. Mitchell has participated in advisory boards for AstraZeneca, GlaxoSmithKline, Sanofi and has received grant support from Teva in the past.